Comparison of atorvastatin and simvastatin in prevention of atrial fibrillation after successful cardioversion

International Heart Journal

Volumn 50, Issue 2, 2009, Pages 153-160

  Naji, Franjo ^a   Suran, David ^a   Kanic, Vojko ^a   Vokac, Damijan ^a   Sabovic, Miso ^b  

^a UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Atorvastatin; Atrial fibrillation; Electrical cardioversion; Pleiotropic effects; Simvastatin; Sinus rhythm

Indexed keywords

AMIODARONE; ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN; ANTIARRHYTHMIC AGENT; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

ADULT; ARTICLE; CARDIOVERSION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MYALGIA; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; SIDE EFFECT; SINUS RHYTHM; AGED; ELECTROCARDIOGRAPHY; MIDDLE AGED; RISK; STATISTICAL MODEL; TREATMENT OUTCOME;

AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ELECTRIC COUNTERSHOCK; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PYRROLES; RETROSPECTIVE STUDIES; SIMVASTATIN; TREATMENT OUTCOME;

EID: 67449100068     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.50.153     Document Type: Article

References (20)

1. Ueng KC, Tsai TP, Yu WC, et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003; 24: 2090-8.
2. Komatsu T, Ozawa M, Tachibana H, et al. Combination therapy with amiodarone and enalapril in patients with paroxysmal atrial fibrillation prevents the development of structural atrial remodeling. Int Heart J 2008; 49: 435-47.
3. Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002; 106: 331-6.
4. Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2003; 92: 1343-5.
5. Ishiguro H, Ikeda T, Abe A, et al. Antiarrhythmic effect of bisoprolol, a highly selective beta 1-blocker, in patients with paroxysmal atrial fibrillation. Int Heart J 2008; 49: 281-93.
6. Tamargo J, Caballero R, Gómez R, Núñez L, Vaquero M, Delpón E. Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapy. Pharmacol Ther 2007; 114: 107-26. (Review)
7. Humphries KH, Lee M, Sheldon R, et al. Statin use and recurrence of atrial fibrillation after successful cardioversion. Am Heart J 2007; 154: 908-13.
8. Patti G, Chello M, Candura D, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 2006; 114: 1455-61.
9. Patel AA, White CM, Shah SA, Dale KM, Kluger J, Coleman CI. The relationship between statin use and atrial fibrillation. Curr Med Res Opin 2007; 23: 1177-85.
10. Liu T, Li L, Korantzopoulos P, Liu E, Li G. Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies. Int J Cardiol 2008; 126: 160-70.
11. Turner NA, Midgley L, O'Regan DJ, Porter KE. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion. J Cardiovasc Pharmacol 2007; 50: 458-61.
12. Strandberg TE, Vanhanen H, Tikkanen MJ. Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet 1999; 353: 118-9.
13. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-35.
14. Rosenson RS. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis 2004; 173: 1-12. (Review)
15. Hognestad A, Aukrust P, Wergeland R, et al. Effects of conventional and aggressive statin treatment on markers of endothelial function and inflammation. Clin Cardiol 2004; 27: 199-203.
16. Mulder DJ, van Haelst PL, Wobbes MH, et al. The effect of aggressive versus conventional lipidlowering therapy on markers of inflammatory and oxidative stress. Cardiovasc Drugs Ther 2007; 21: 91-7.
17. Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol 2007; 50: 2021-8. (Review)
18. Yamada T, Murakami Y, Okada T, et al. Plasma brain natriuretic peptide level after hybrid therapy with pulmonary vein isolation and antiarrhythmic drugs for atrial fibrillation. Int Heart J 2008; 49: 143-51.
19. Ozaydin M, Varol E, Aslan SM, et al. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am J Cardiol 2006; 97: 1490-3.
20. Tveit A, Grundtvig M, Gundersen T, et al. Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 2004; 93: 780-2.